Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2024 | Cytometry versus morphology in the monitoring of AML

Sanam Loghavi • 14 Jun 2024
EHA 2024
Acute Myeloid Leukemia Leukemia

Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the potential of replacing morphology with flow cytometry for monitoring patients with acute myeloid leukemia (AML). While flow cytometry is highly sensitive and specific for detecting residual AML, it has limitations. Therefore, Dr Loghavi recommends using it in combination with morphology for optimal surveillance. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Sanam Loghavi

9:41
The i4MDS consortium and immune monitoring in MDS
Sanam Loghavi et al. • 13 Jun 2024
1:04
Optical genome mapping to detect abnormalities in AML
Sanam Loghavi • 14 Jun 2024
1:46
Challenges in utilizing mutation testing in AML
Sanam Loghavi • 14 Jun 2024
1:30
Immunophenotypic changes induced by menin inhibition in AML
Sanam Loghavi • 14 Jun 2024

Related Videos

0:43
Reducing chemotherapy-induced adverse events in patients with AML
Fabio Guolo • 16 Jun 2024
3:24
Pre-induction azacitidine and venetoclax to improve the bone marrow microenvironment in AML
Maher Salamoon • 26 Jun 2024
4:41
Intrathecal rituximab plus dexamethasone in B-cell malignancies with CNS involvement
Maher Salamoon • 26 Jun 2024
4:31
The impact of high and low burden TP53 mutations on risk and treatment decision in CLL
Maher Salamoon • 26 Jun 2024
The content of VJHemOnc is intended for healthcare professionals